M. D. Anderson Cancer Center - News Releases

Sheba and M. D. Anderson Sign Cooperation Agreement in Cancer Treatment and Research

2010-02-01T20:47:48Z

The Chaim Sheba Medical Center and The University of Texas M. D. Anderson Cancer Center today signed a pioneering Sister Institution Relationship agreement for broad-scale cooperation in oncology training, treatment and research.

Researchers Find Leukemia Cells Metabolize Fat to Avoid Cell Death

2010-01-27T21:54:35Z

Leukemia cells, like most cancers, are addicted to glucose to generate their energy, but new research shows for the first time that these cells also rely on fatty acid metabolism to grow and to evade cell death.

Major Grant Amplifies Efforts of Childhood Anti-Obesity Alliance

2010-01-12T22:08:06Z

CAN DO Houston (Children and Neighbors Defeating Obesity) will expand its community-based efforts with a $360,000 grant from the Robert Wood Johnson Foundation's "Healthy Kids, Healthy Communities" initiative.

Growth Factor Hit by Cancer Drugs also Protects Heart

2010-01-12T15:38:05Z

A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at The University of Texas M. D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

Arap, Pasqualini Earn O'Donnell Award from Texas Academy

2010-01-07T22:09:26Z

Two scientists who discovered that blood vessels supplying different organs and tissues have unique molecular signatures which may be exploited to develop highly targeted therapies will receive the 2010 Edith and Peter O'Donnell Award in Medicine from The Academy of Medicine, Engineering and Science of Texas.

Novel Detection Method Unmasks Circulating Breast Cancer Cells

2009-12-14T14:03:16Z

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

M. D. Anderson Study Finds Racial Disparities Exist in Radiation Therapy Rates for Early Stage Breast Cancer

2009-12-14T13:58:45Z

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center.

M. D. Anderson Study Questions True Favorability of Rare Breast Cancer Type

2009-12-14T13:57:32Z

In a large review of breast cancer patients with mucinous carcinoma, researchers at The University of Texas M. D. Anderson Cancer Center have identified an association between this rare type of breast cancer long-associated with a favorable prognosis and multiple tumors undetected by mammography or ultrasound.

Sonic Hedgehog Pathway Variations Linked to Recurrence, Survival and Response to Therapy of Non-Invasive Bladder Cancer Patients

2009-12-09T21:10:09Z

Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

Genetic Variations Indicate Risk of Recurrence, Secondary Cancer Among Head and Neck Cancer Patients

2009-12-07T21:50:08Z

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

Second-line CML Drugs Evoke Faster Response than Front-line Therapy

2009-12-07T21:49:02Z

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

Drug Shows Positive Responses, Low Side-Effects in Multiple Myeloma

2009-12-07T20:20:15Z

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

Drug Shows Promise for T315I-Mutated Chronic Myeloid Leukemia

2009-12-07T20:19:13Z

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

JAK2 Inhibitor Demonstrates Effective, Durable Control of Myelofibrosis

2009-12-07T20:18:04Z

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

Susceptibility Predicts Smoking Risk among Mexican-American Youth

2009-12-04T14:49:41Z

Whether non-smoking Mexican-American adolescents go on to experiment with smoking depends largely on their initial attitude toward the habit, researchers at M. D. Anderson Cancer Center report in the December issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.